Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Amortization of Deferred Charges (2022 - 2025)

Historic Amortization of Deferred Charges for Immucell (ICCC) over the last 4 years, with Q3 2025 value amounting to $29578.0.

  • Immucell's Amortization of Deferred Charges rose 17374.36% to $29578.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $61997.0, marking a year-over-year increase of 4778.08%. This contributed to the annual value of $42666.0 for FY2024, which is 8862.9% up from last year.
  • Immucell's Amortization of Deferred Charges amounted to $29578.0 in Q3 2025, which was up 17374.36% from $10806.0 recorded in Q2 2025.
  • Immucell's Amortization of Deferred Charges' 5-year high stood at $29578.0 during Q3 2025, with a 5-year trough of $1915.0 in Q2 2022.
  • In the last 4 years, Immucell's Amortization of Deferred Charges had a median value of $10170.5 in 2023 and averaged $8730.5.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first soared by 46310.58% in 2024, then changed by 0.0% in 2025.
  • Immucell's Amortization of Deferred Charges (Quarter) stood at $1919.0 in 2022, then skyrocketed by 426.0% to $10094.0 in 2023, then grew by 7.06% to $10807.0 in 2024, then skyrocketed by 173.69% to $29578.0 in 2025.
  • Its Amortization of Deferred Charges stands at $29578.0 for Q3 2025, versus $10806.0 for Q2 2025 and $10806.0 for Q1 2025.